Latest & greatest articles for epilepsy

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on epilepsy or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on epilepsy and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for epilepsy

61. Practice Guideline Update Summary: Efficacy and Tolerability of the New Antiepileptic Drugs II: Treatment-resistant Epilepsy

Practice Guideline Update Summary: Efficacy and Tolerability of the New Antiepileptic Drugs II: Treatment-resistant Epilepsy AAN.com ©2018 American Academy of Neurology AAN and AES Summary of Practice Guideline for Clinicians Practice Guideline Update: Efficacy and Tolerability of the New Antiepileptic Drugs II: Treatment-resistant Epilepsy This is a summary of the American Academy of Neurology (AAN) and American Epilepsy Society (AES) practice guideline, “Practice guideline update: Efficacy (...) and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy,” which was published online ahead of print in Neurology ® on June 13, 2018. It will appear in the July 10, 2018, print issue. Please refer to the full guideline at AAN.com/guidelines for more information, including descriptions of the processes for classifying evidence, deriving conclusions, and making recommendations. For adult patients with treatment-resistant (TR) focal epilepsy, are these antiepileptic drugs (AEDs

2018 American Academy of Neurology

62. Eslicarbazepine acetate (Zebinix) - treatment of partial-onset seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy

Eslicarbazepine acetate (Zebinix) - treatment of partial-onset seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy Non Submission eslicarbazepine acetate 200mg and 800mg tablets (Zebinix ® ) SMC2090 Eisai Ltd 4 May 2018 ADVICE: in the absence of a submission from the holder of the marketing authorisation eslicarbazepine acetate (Zebinix ® ) is not recommended for use within NHS Scotland. Indication under review: As monotherapy in the treatment of partial (...) -onset seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland. Advice context: No part of this advice may be used without the whole of the advice being quoted in full. This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area

2018 Scottish Medicines Consortium

63. Incorporating epilepsy genetics into clinical practice: a 360°evaluation (PubMed)

Incorporating epilepsy genetics into clinical practice: a 360°evaluation We evaluated a new epilepsy genetic diagnostic and counseling service covering a UK population of 3.5 million. We calculated diagnostic yield, estimated clinical impact, and surveyed referring clinicians and families. We costed alternative investigational pathways for neonatal onset epilepsy. Patients with epilepsy of unknown aetiology onset < 2 years; treatment resistant epilepsy; or familial epilepsy were referred (...) for counseling and testing. We developed NGS panels, performing clinical interpretation with a multidisciplinary team. We held an educational workshop for paediatricians and nurses. We sent questionnaires to referring paediatricians and families. We analysed investigation costs for 16 neonatal epilepsy patients. Of 96 patients, a genetic diagnosis was made in 34% of patients with seizure onset < 2 years, and 4% > 2 years, with turnaround time of 21 days. Pathogenic variants were seen in SCN8A, SCN2A, SCN1A

Full Text available with Trip Pro

2018 NPJ genomic medicine

64. Stiripentol add-on therapy for focal refractory epilepsy. (PubMed)

Stiripentol add-on therapy for focal refractory epilepsy. This is an updated version of the Cochrane review last published in 2015 (Issue 10). For nearly 30% of people with epilepsy, seizures are not controlled by current treatments. Stiripentol is a new antiepileptic drug (AED) that was developed in France and was approved by the European Medicines Agency (EMA) in 2007 for the treatment of Dravet syndrome as an adjunctive therapy with valproate and clobazam, with promising effects.To evaluate (...) the efficacy and tolerability of stiripentol as add-on treatment for people with focal refractory epilepsy who are taking AEDs.For the latest update, we searched the following databases on 21 August 2017: Cochrane Epilepsy Specialized Register, CENTRAL , MEDLINE, ClinicalTrials.gov, and the WHO International Clinical Trials Registry Platform (ICTRP). We contacted Biocodex (the manufacturer of stiripentol) and epilepsy experts to identify published, unpublished and ongoing trials.Randomised, controlled, add

2018 Cochrane

65. Exploring the perception of women with epilepsy about pregnancy concerns: a qualitative study (PubMed)

Exploring the perception of women with epilepsy about pregnancy concerns: a qualitative study Epilepsy is a common neurological disorder in pregnancy, which is associated with increased maternal and fetal adverse outcomes. This study aimed to explore the reproductive healthcare needs of women with epilepsy before, during and after childbirth.This was a qualitative study using a content analysis method. The study population was marital women with epilepsy in reproductive age (15-45 years (...) for women with epilepsy, (2) doubt about the advantages and disadvantages of breastfeeding, (3) stigma as a block to the treatment of the postpartum depression, and (4) playing the motherhood role under the shadow of self-esteem to lack of self-esteem.In the prenatal, natal and postnatal duration, because of supportive system disruption and not receiving proper consultation, participants were often worried about not being able to get favorable conditions for safe pregnancy and controlling process

Full Text available with Trip Pro

2018 Electronic physician

66. Clonazepam add-on therapy for refractory epilepsy in adults and children. (PubMed)

Clonazepam add-on therapy for refractory epilepsy in adults and children. Epilepsy affects about 50 million people worldwide, nearly a quarter of whom have drug-refractory epilepsy. People with drug-refractory epilepsy have increased risks of premature death, injuries, psychosocial dysfunction, and a reduced quality of life.To assess the efficacy and tolerability of clonazepam when used as an add-on therapy for adults and children with refractory focal onset or generalised onset epileptic (...) seizures, when compared with placebo or another antiepileptic agent.We searched the following databases on 14 September 2017: Cochrane Epilepsy Group Specialized Register, Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (CRSO), MEDLINE (Ovid 1946 to 14 September 2017), ClinicalTrials.gov, and the WHO International Clinical Trials Registry Platform (ICTRP).Double-blind randomised controlled studies of add-on clonazepam in people with refractory focal

2018 Cochrane

67. Epilepsy in Children After Pandemic Influenza Vaccination

Epilepsy in Children After Pandemic Influenza Vaccination To determine if pandemic influenza vaccination was associated with an increased risk of epilepsy in children.Information from Norwegian registries from 2006 through 2014 on all children <18 years living in Norway on October 1, 2009 was used in Cox regression models to estimate hazard ratios for incident epilepsy after vaccination. A self-controlled case series analysis was used to estimate incidence rate ratios in defined risk periods (...) after pandemic vaccination.In Norway, the main period of the influenza A subtype H1N1 pandemic was from October 2009 to December 2009. On October 1, 2009, 1 154 113 children <18 years of age were registered as residents in Norway. Of these, 572 875 (50.7%) were vaccinated against pandemic influenza. From October 2009 through 2014 there were 3628 new cases of epilepsy (incidence rate 6.09 per 10 000 person-years). The risk of epilepsy was not increased after vaccination: hazard ratio: 1.07; 95

2018 EvidenceUpdates

68. Self-Management education for adults with poorly controlled epILEpsy [SMILE (UK)]: a randomised controlled trial

Self-Management education for adults with poorly controlled epILEpsy [SMILE (UK)]: a randomised controlled trial Self-Management education for adults with poorly controlled epILEpsy [SMILE (UK)]: a randomised controlled trial Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find (...) the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} For adults with epilepsy and persistent seizures, a 2-day group course increased their self-confidence, but did not change their quality of life 12 months later. {{author}} {{($index , , , , , , , , , , , , & . Leone Ridsdale 1, * , Alison McKinlay 1 , Gabriella Wojewodka 1 , Emily J Robinson 2 , Iris Mosweu 3 , Sarah J Feehan 1 , Adam J Noble 4 , Myfanwy Morgan 5 , Stephanie J C

2018 NIHR HTA programme

69. Rufinamide add-on therapy for refractory epilepsy. (PubMed)

Rufinamide add-on therapy for refractory epilepsy. Epilepsy is a central nervous system disorder (neurological disorder). Epileptic seizures are the result of excessive and abnormal cortical nerve cell electrical activity in the brain. Despite the development of more than 10 new antiepileptic drugs (AEDs) since the early 2000s, approximately a third of people with epilepsy remain resistant to pharmacotherapy, often requiring treatment with a combination of AEDs. In this review, we summarised (...) the current evidence regarding rufinamide, a novel anticonvulsant medication, which, as a triazole derivative, is structurally unrelated to any other currently used anticonvulsant medication, when used as an add-on treatment for refractory epilepsy. In January 2009, rufinamide was approved by the US Food and Drug Administration for treatment of children four years of age and older with Lennox-Gastaut syndrome. It is also approved as an add-on treatment for adults and adolescents with focal seizures.To

2018 Cochrane

70. A range of anti-epilepsy drugs are effective as first-line treatment

A range of anti-epilepsy drugs are effective as first-line treatment A range of anti-epilepsy drugs are effective as first-line treatment Discover Portal Discover Portal A range of anti-epilepsy drugs are effective as first-line treatment Published on 12 September 2017 doi: Lamotrigine and levetiracetam are emerging as first-line treatments for epilepsy, which people may be more likely to keep taking than carbamazepine. Reducing the risk of adverse events and treatment withdrawal is important (...) when selecting an anti-epilepsy drug as it usually will need to be taken long-term. This study reviewed evidence on anti-epilepsy drugs in adults and children. The drugs were compared directly or indirectly with each other. The main outcome of interest was time to withdrawal from treatment, which indicates effectiveness and tolerability. The findings support NICE recommendations to use carbamazepine or lamotrigine as first-line therapies for epilepsy with partial seizures, with levetiracetam

2018 NIHR Dissemination Centre

71. Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence

Evidence for cannabis and cannabinoids for epilepsy: a systematic review of controlled and observational evidence Review evidence for cannabinoids as adjunctive treatments for treatment-resistant epilepsy. Systematic search of Medline, Embase and PsycINFO was conducted in October 2017. Outcomes were: 50%+ seizure reduction, complete seizure freedom; improved quality of life (QoL). Tolerability/safety were assessed by study withdrawals, adverse events (AEs) and serious adverse events (SAEs (...) % (95% CI 3.8% to 14.5%) were seizure-free. Twelve observational studies reported improved QoL (55.8%, 95% CI 40.5 to 70.6); 50.6% (95% CI 31.7 to 69.4) AEs and 2.2% (95% CI 0 to 7.9) SAEs. Pharmaceutical-grade CBD as adjuvant treatment in paediatric-onset drug-resistant epilepsy may reduce seizure frequency. Existing RCT evidence is mostly in paediatric samples with rare and severe epilepsy syndromes; RCTs examining other syndromes and cannabinoids are needed.CRD42017055412.© Article author(s

Full Text available with Trip Pro

2018 EvidenceUpdates

72. Epilepsy, antiepileptic drugs, and serious transport accidents: A nationwide cohort study

Epilepsy, antiepileptic drugs, and serious transport accidents: A nationwide cohort study To investigate the association between epilepsy and antiepileptic drugs and serious transport accidents requiring emergency care or resulting in death.We identified 29,220 individuals 18 years or older with epilepsy without cerebral palsy or intellectual disability and 267,637 matched controls using Swedish registers. This nationwide cohort was followed from 2006 to 2013 for serious transport accidents. We (...) used Cox regression to analyze the risk of serious transport accidents between individuals with epilepsy and matched controls, and then stratified Cox regression to compare the risk during periods of medication with the risk during nonmedication period within the same individual with epilepsy. We adjusted for civil status, employment, education, living area, psychiatric disorders prior to the start of follow-up, and psychotropic medication.Compared to matched controls, individuals with epilepsy

2018 EvidenceUpdates

73. Cardiac arrhythmia and neuroexcitability gene variants in resected brain tissue from patients with sudden unexpected death in epilepsy (SUDEP) (PubMed)

Cardiac arrhythmia and neuroexcitability gene variants in resected brain tissue from patients with sudden unexpected death in epilepsy (SUDEP) Sudden unexpected death in epilepsy (SUDEP) is the leading cause of epilepsy-related mortality in young adults. The exact mechanisms are unknown but death often follows a generalized tonic-clonic seizure. Proposed mechanisms include seizure-related respiratory, cardiac, autonomic, and arousal dysfunction. Genetic drivers underlying SUDEP risk are largely (...) unknown. To identify potential SUDEP risk genes, we compared whole-exome sequences (WES) derived from formalin-fixed paraffin embedded surgical brain specimens of eight epilepsy patients who died from SUDEP with seven living controls matched for age at surgery, sex, year of surgery and lobe of resection. We compared identified variants from both groups filtering known polymorphisms from publicly available data as well as scanned for epilepsy and candidate SUDEP genes. In the SUDEP cohort, we

Full Text available with Trip Pro

2018 NPJ genomic medicine

74. Variant Intestinal-Cell Kinase in Juvenile Myoclonic Epilepsy. (PubMed)

Variant Intestinal-Cell Kinase in Juvenile Myoclonic Epilepsy. In juvenile myoclonic epilepsy, data are limited on the genetic basis of networks promoting convulsions with diffuse polyspikes on electroencephalography (EEG) and the subtle microscopic brain dysplasia called microdysgenesis.Using Sanger sequencing, we sequenced the exomes of six members of a large family affected with juvenile myoclonic epilepsy and confirmed cosegregation in all 37 family members. We screened an additional 310 (...) in mice lacking a copy of Ick.A variant, K305T (c.914A→C), cosegregated with epilepsy or polyspikes on EEG in 12 members of the family affected with juvenile myoclonic epilepsy. We identified 21 pathogenic ICK variants in 22 of 310 additional patients (7%). Four strongly linked variants (K220E, K305T, A615T, and R632X) impaired mitosis, cell-cycle exit, and radial neuroblast migration while promoting apoptosis. Tonic-clonic convulsions and polyspikes on EEG resembling seizures in human juvenile

Full Text available with Trip Pro

2018 NEJM

75. Behavioral interventions as a treatment for epilepsy: A multicenter randomized controlled trial

Behavioral interventions as a treatment for epilepsy: A multicenter randomized controlled trial To evaluate the effect of a stress-reduction intervention in participants with medication-resistant epilepsy.Adults with medication-resistant focal epilepsy (n = 66) were recruited from 3 centers and randomized to 1 of 2 interventions: (1) progressive muscle relaxation (PMR) with diaphragmatic breathing, or (2) control focused-attention activity with extremity movements. Following an 8-week baseline

2018 EvidenceUpdates

76. Care delivery and self-management strategies for children with epilepsy. (PubMed)

Care delivery and self-management strategies for children with epilepsy. In response to criticism that epilepsy care for children has little impact, healthcare professionals and administrators have developed various service models and strategies to address perceived inadequacies.To assess the effects of any specialised or dedicated intervention for epilepsy versus usual care in children with epilepsy and in their families.We searched the Cochrane Epilepsy Group Specialized Register (27 (...) September 2016), the Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 9) in the Cochrane Library, MEDLINE (1946 to 27 September 2016), Embase (1974 to 27 September 2016), PsycINFO (1887 to 27 September 2016) and CINAHL Plus (1937 to 27 September 2016). In addition, we also searched clinical trials registries for ongoing or recently completed trials, contacted experts in the field to seek information on unpublished and ongoing studies, checked the websites of epilepsy organisations

2018 Cochrane

77. Training nurses in a competency framework to support adults with epilepsy and intellectual disability: the EpAID cluster RCT

Training nurses in a competency framework to support adults with epilepsy and intellectual disability: the EpAID cluster RCT Training nurses in a competency framework to support adults with epilepsy and intellectual disability: the EpAID cluster RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search (...) above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} The competency framework conferred no clinical benefit, compared to treatment as usual, in reducing seizure severity in adults with epilepsy and learning disability. {{author}} {{($index , , , , , , , , , , , , , , , & . Howard Ring 1, 2, 3, * , James Howlett 4 , Mark Pennington 5 , Christopher Smith 1 , Marcus Redley 1, 3, 6 , Caroline Murphy 7 , Roxanne

2018 NIHR HTA programme

78. Nephrolithiasis and Nephrocalcinosis From Topiramate Therapy in Children With Epilepsy (PubMed)

Nephrolithiasis and Nephrocalcinosis From Topiramate Therapy in Children With Epilepsy Adults treated with topiramate may develop nephrolithiasis, but its frequency in children on topiramate is unknown. Topiramate inhibits renal carbonic anhydrase, which can lead to renal tubular acidosis and hypercalciuria. We studied 40 consecutive children who initiated topiramate therapy for seizures between January 1997 and February 2003, followed for a mean of 36 months.Serum electrolytes, urinary

Full Text available with Trip Pro

2018 Kidney international reports

79. Polysomnographic Aspects of Sleep Architecture on Self-limited Epilepsy with Centrotemporal Spikes: A Systematic Review and Meta-analysis. (PubMed)

Polysomnographic Aspects of Sleep Architecture on Self-limited Epilepsy with Centrotemporal Spikes: A Systematic Review and Meta-analysis. Self-limited epilepsy with centrotemporal spikes is the most common paediatric epileptic syndrome, with growing evidence linking it to various degrees and presentations of neuropsychological dysfunction. The objective of this study is to evaluate the possible sleep macro and microstructural alterations in children with this diagnosis. A systematic review (...) of published manuscripts was carried out in Medline, LILACS and Scielo databases, using the MeSH terms epilepsy, sleep and polysomnography. From 753 retrieved references, 5 were selected, and data from macro and, when available, microstructure of sleep were extracted. Meta-analysis was performed with data from 4 studies using standardized mean difference. Findings were heterogeneous between studies, being the most frequent macrostructural findings a smaller proportion and greater latency of REM sleep

Full Text available with Trip Pro

2018 Sleep science (Sao Paulo, Brazil)

80. Five and 10 minute Apgar scores and risks of cerebral palsy and epilepsy: population based cohort study in Sweden. (PubMed)

Five and 10 minute Apgar scores and risks of cerebral palsy and epilepsy: population based cohort study in Sweden. To investigate associations between Apgar score at five and 10 minutes across the entire range of score values (from 0 to 10) and risks of childhood cerebral palsy or epilepsy, and to analyse the effect of changes in Apgar scores from five to 10 minutes after birth in infants born ≥37 completed weeks.Population based cohort study in Sweden, including 1 213 470 non-malformed live (...) singleton infants, born at term between 1999 and 2012. Data on maternal and pregnancy characteristics and diagnoses of cerebral palsy and epilepsy were obtained by individual record linkages of nationwide Swedish registries.Apgar scores at five and 10 minutes.Cerebral palsy and epilepsy diagnosed up to 16 years of age. Adjusted hazard ratios were calculated, along with 95% confidence intervals.1221 (0.1%) children were diagnosed as having cerebral palsy and 3975 (0.3%) as having epilepsy. Compared

Full Text available with Trip Pro

2018 BMJ